Interaction of ICRF 159 with radiation, and its effect on sub-lethal and potentially lethal radiation damage in vitro
- PMID: 588416
- PMCID: PMC2025374
- DOI: 10.1038/bjc.1977.219
Interaction of ICRF 159 with radiation, and its effect on sub-lethal and potentially lethal radiation damage in vitro
Abstract
ICRF 159 has been shown to increase the X-radiation sensitivity of exponentially growing EMT6 mouse tumour cells in vitro. This was found only with ICRF 159 exposure times longer than 10 h and only when the drug was given before irradiation. The increase in radiation sensitivity was expressed as a reduction of the shoulder of the radiation survival curve. As ICRF 159 was shown to have no effect on the repair of sub-lethal radiation damage, it was concluded that the drug reduced the capacity to accumulate such damage. ICRF 159 was also shown to have no effect on the repair of potentially lethal radiation damage in late plateau cells.
Similar articles
-
Changes in sensitivity to radiation and ICRF 159 during the life of monolayer cultures of EMT6 tumour line.Br J Cancer. 1977 May;35(5):587-94. doi: 10.1038/bjc.1977.92. Br J Cancer. 1977. PMID: 861147 Free PMC article.
-
Radiation survival properties of cultured human gastric adenocarcinoma cells and the effect of AT-1727.Int J Radiat Oncol Biol Phys. 1989 Feb;16(2):361-8. Int J Radiat Oncol Biol Phys. 1989. PMID: 2921140
-
Biological properties of ICRF-159 and related bis(dioxopiperazine) compounds.Adv Pharmacol Chemother. 1982;19:249-90. doi: 10.1016/s1054-3589(08)60025-3. Adv Pharmacol Chemother. 1982. PMID: 6819768 Review. No abstract available.
-
Interaction of razoxane and radiation on cultured Chinese hamster cells.Int J Radiat Oncol Biol Phys. 1982 Aug;8(8):1333-8. doi: 10.1016/0360-3016(82)90583-1. Int J Radiat Oncol Biol Phys. 1982. PMID: 7141912
-
A linear-quadratic model of cell survival considering both sublethal and potentially lethal radiation damage.Radiother Oncol. 1991 Aug;21(4):273-6. doi: 10.1016/0167-8140(91)90053-j. Radiother Oncol. 1991. PMID: 1924866 Review.
Cited by
-
ICRF-159 enhancement of radiation response in combined modality therapies. I. Time/dose relationships for tumour response.Br J Cancer. 1979 May;39(5):516-23. doi: 10.1038/bjc.1979.95. Br J Cancer. 1979. PMID: 486307 Free PMC article.
-
Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumour agent ICRF 159 and its inactive homologue ICRF 192.Agents Actions. 1982 Oct;12(4):536-42. doi: 10.1007/BF01965940. Agents Actions. 1982. PMID: 7180739
-
ICRF-159 enhancement of radiation response in combined modality therapies. II. Differential responses of tumour and normal tissues.Br J Cancer. 1979 May;39(5):524-30. doi: 10.1038/bjc.1979.96. Br J Cancer. 1979. PMID: 486308 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials